McKesson Corporation today announced the launch of InspiroGene™ by McKesson, a dedicated business focused exclusively on supporting the commercialization of cell and gene therapies (CGTs). This initiative aims to help manufacturers, payers, and providers navigate the intricate CGT commercialization landscape, ensuring that patients gain access to vital treatments.
“Over the last few years, McKesson has leveraged its extensive supply chain expertise and customer-centric approach to build our cell and gene therapy business, with a focus on guiding innovative medicines from clinical development to commercial success,” stated Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson. “Today’s launch of InspiroGene by McKesson is an exciting step forward in our evolution, with a new brand that reflects the work we are doing to transform care for patients and advance health outcomes for all.”
InspiroGene is equipped with extensive experience across the entire CGT life cycle and has developed several solutions to address the unique challenges associated with bringing CGTs to market:
-
Third-party logistics (3PL) programs tailored to meet the specific needs of CGT manufacturers, incorporating financial management solutions, logistics, and advanced data analytics for streamlined operations.
-
Specialty distribution services utilizing McKesson’s vast supply chain network to ensure CGTs are delivered to patients efficiently, supported by high-touch logistics and sophisticated data analytics.
-
Biologics specialty pharmacy solutions for CGTs, featuring precision dispensing to accelerate time to treatment and comprehensive patient management services addressing unique therapy requirements.
-
A CGT dedicated patient hub offering customized access and support services for patients, alongside operational case management for providers, patients, and caregivers.
Additionally, InspiroGene presents a technology platform that enhances visibility within the CGT value chain by integrating product data and financial flows, empowering CGT manufacturers, providers, and patients to deliver exceptional care and achieve transformative clinical outcomes.
About InspiroGene by McKesson
InspiroGene by McKesson (“InspiroGene”) is a dedicated business focused solely on supporting the commercialization of cell and gene therapies (CGTs). At InspiroGene, we turn CGT innovation into a reality. We offer flexible, sustainable solutions to help manufacturers, payers, and providers navigate the complex CGT commercialization landscape. As an enduring ally, we’re dedicated to transforming patient care and driving better health outcomes. Learn more about the InspiroGene advantage at InspiroGene.com.
